UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044378
Receipt number R000050693
Scientific Title Safety confirmation studies of excessive intake of food including Extract of Salmon Nasal Cartilage in healthy adult men and women.
Date of disclosure of the study information 2021/05/31
Last modified on 2022/03/24 10:07:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety evaluation

Acronym

Safety evaluation

Scientific Title

Safety confirmation studies of excessive intake of food including Extract of Salmon Nasal Cartilage in healthy adult men and women.

Scientific Title:Acronym

Safety confirmation studies of excessive intake of food including Extract of Salmon Nasal Cartilage in healthy adult men and women.

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety of excessive intake of food including Extract of Salmon Nasal Cartilage 5 times as much as the recommended daily intake for 4 weeks.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Hematologic test
Blood biochemistry test
Urine analysis
Blood pressure/pulsation
Weight/body mass index
Adverse event
Evaluate at points of 2 week and 4 week of intake and 2 weeks after the end of ingestion period

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral intake 5 capsules of the test product daily for 4 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

Healthy adult men and women between the ages of 20 and 64.

Key exclusion criteria

(1) Subjects who are judged as unsuitable for this study by the principal investigator based on the results of clinical examination or cardiopulmonary abnormality
(2) Subjects having possibilities for emerging allergy related to the study
(3) Subjects having a disease requiring regular medication or a history of serious diseases for which medication was required
(4) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination
(5) Subjects who have participated in other clinical studies
(6) Subjects who intend to become pregnant or lactating
(7) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire
(8) Subjects judged as unsuitable for the study by the investigator for other reasons

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Jiro
Middle name
Last name Saito

Organization

Medical Station Clinic

Division name

None

Zip code

152-0004

Address

3-12-8, Takaban, Meguro-ku, Tokyo, Japan

TEL

03-6452-2712

Email

info@med-station.jp


Public contact

Name of contact person

1st name Keiji
Middle name
Last name Yamamoto

Organization

EP Mediate Co., Ltd.

Division name

Development Business Headquarters, TTC Center, Trial Planning Department

Zip code

162-0822

Address

Tsuruya Bldg., 2-23 Shimomiyabicho, Shinjuku-ku, Tokyo

TEL

03-5657-4983

Homepage URL


Email

yamamoto799@eps.co.jp


Sponsor or person

Institute

EP Mediate Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Egao Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Station Clinic Research Ethics Committee

Address

3-12-8, Takaban, Meguroku, Tokyo

Tel

03-6452-2712

Email

saito876@eps.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 05 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

10

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 05 Month 27 Day

Date of IRB

2021 Year 05 Month 27 Day

Anticipated trial start date

2021 Year 06 Month 08 Day

Last follow-up date

2021 Year 08 Month 10 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 05 Month 31 Day

Last modified on

2022 Year 03 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050693


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name